Next 10 |
2024-03-25 14:04:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors got a good case of whiplash over the past four years. The pandemic crash of 2020 brought a decade-long bull market to a screeching halt. However, the spin-up into the revenge-buying b...
2024-03-14 12:44:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the growing demand for telemedicine, the market could be worth about $450 billion by the time 2032 rolls around. That’s according to Emergen Research. By 2034, it could hit $8...
2024-03-12 13:00:03 ET Shagun Singh from RBC Capital issued a price target of $165.00 for DXCM on 2024-03-12 11:54:00. The adjusted price target was set to $165.00. At the time of the announcement, DXCM was trading at $134.475. The overall price target consensus is at $7...
2024-03-12 12:52:20 ET More on DexCom DexCom: A Wealth Compounder In Healthcare DexCom, Inc. (DXCM) Q4 2023 Earnings Call Transcript DexCom, Inc. 2023 Q4 - Results - Earnings Call Presentation FDA approves Dexcom's Stelo glucose monitor for OTC use Ti...
2024-03-10 13:00:53 ET More on the markets S&P 500: Time To Hedge, Here's How How The S&P 500 Could Actually Be Closer To 4,200 Than 5,000 SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat Cata...
2024-03-08 09:15:00 ET A good way to invest in the healthcare industry's continued growth is by targeting businesses that make medical devices. Such equipment aids physicians in surgery, helps patients recover, and can assist people in staying on top of chronic conditions, including hyperte...
2024-03-08 08:43:37 ET More on Insulet Insulet Corporation (PODD) Q4 2023 Earnings Call Transcript Insulet: An Interesting, Yet Expensive, Story Insulet Non-GAAP EPS of $1.40 beats by $0.74, revenue of $509.8M beats by $48.74M Insulet Q4 2023 Earnings Preview...
2024-03-07 14:54:51 ET Summary iShares Russell Mid-Cap Growth ETF uses one valuation and two growth metrics to pick mid-cap stocks. The portfolio is well-diversified and quality metrics look good. The IWP ETF has recently outperformed competitors, and trading volumes can satis...
Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor worn on the back of the upper arm, Stelo will provide glucose insights directly to a user...
New data shows long-term use of an AID system powered by Dexcom CGM can safely maintain improvements in glycaemic outcomes for up to two years 1. Real-world evidence demonstrates reduction in severe hypoglycaemia and diabetic ketoacidosis over 12 months in people with Type 1 diabetes ...
News, Short Squeeze, Breakout and More Instantly...
DexCom Inc’s (NASDAQ: DXCM) Stelo Glucose Biosensor System has been approved by the Food and Drug Administration (FDA) as the first over-the-...